Single-lead ECG tracings from an Apple Watch interpreted by an artificial intelligence (AI) algorithm developed at Mayo Clinic effectively identified patients with a weak heart pump. To interpret ECG signals generated from the single lead on an Apple Watch, researchers modified an established 12-lead algorithm for low ventricular ejection fraction—the weak heart pump—that is licensed to Anumana Inc., an AI-driven health technology company, by nference and Mayo Clinic.

Researchers use AI to detect weak heart pump via patients' Apple Watch ECGs

Patients with a weak heart pump were identified using single-lead ECG tracings from an Apple Watch interpreted by an artificial intelligence (AI) algorithm developed at Mayo Clinic. Researchers modified an existing 12-lead algorithm for low ventricular ejection fraction — the weak heart pump — that is licensed to Anumana Inc., an AI-driven health technology company, by nference and Mayo Clinic, to interpret ECG signals produced from the single lead on an Apple Watch.

Single-Lead ECG Tracings from an Apple Watch Effectively Identifies Patients with a Weak Heart Pump

Early detection and treatment of heart failure can greatly improve an otherwise poor prognosis. Research from Mayo Clinic suggests artificial intelligence could be used to detect the condition even when no symptoms are present. To interpret ECG signals generated from the single lead on an Apple Watch, researchers at Mayo Clinic modified an established 12-lead algorithm used to detect a weak heart pump. That algorithm is licensed to Anumana, an AI-driven health technology company, by nference, which develops software solutions, and Mayo Clinic.

Could AI and an Apple Watch ECG improve the prognosis for heart failure?

Using simplified ECG data taken from an Apple Watch, researchers at the Mayo Clinic were able to use an artificial intelligence algorithm to spot people whose hearts may be having trouble pumping blood out to the rest of the body. Previously, the algorithms for analyzing 12-lead ECGs—which have received a breakthrough designation from the FDA and an emergency authorization for use against COVID-19—were licensed by nference and Mayo Clinic to Anumana, an AI developer working on their commercialization.

AI researchers at Mayo Clinic use the Apple Watch to detect silent, weakening heart disease

An artificial intelligence (AI) algorithm that uses data from electrocardiography can help increase the diagnosis of low ejection fraction (EF), according to a study published online May 6 in Nature Medicine.

AI Algorithm Aids Early Detection of Low Ejection Fraction

Artificial intelligence (AI) screening helps detect low ejection fraction using data from an EKG could improve the diagnosis of this condition in routine practice. Study findings are published in Nature Medicine.

AI-guided Detection of Heart Disease in Routine Practice

Anumana, a startup designing neural network algorithms to enable early detection and accelerate treatment of heart disease, raised $25.7M led by founders nference and Mayo Clinic, with participation from Matrix Capital Management, Matrix Partners, and NTTVC. 

StartUp Health Insights: Virta & 1Doc3 Close Rounds, Over $1.4B Raised This Week

Anumana will develop and market algorithms for early detection of disease. Lucem Health can collect device data and feed it into clinical workflows. Both spin-offs aim to capitalize on advances in AI and remote telemetry.

Mayo Clinic launches remote diagnostics platform, forms 2 new companies to support it

Mayo Clinic announced that it is introducing a new technology platform to support two new companies it has launched. Rochester, Minn.–based Mayo Clinic’s Remote Diagnostics & Management Platform (RDMP) is designed to connect data with new AI algorithms and augment human decision-making within existing clinical workflows, according to a news release.

Mayo Clinic helps launch two new companies for improved diagnostics

Mayo Clinic last month released a study suggesting that an artificial intelligence (AI) algorithm could be used to better diagnose a certain heart condition called low ejection fraction—one step in the Clinic's effort to incorporate AI into cardiac care more broadly.

How Mayo Clinic is using AI to spot hidden heart conditions

An algorithm developed by the Mayo Clinic can significantly increase the number of cases of low ejection fraction caught in its earliest stages, when it’s still most treatable, according to a study published this month in Nature Medicine.

Mayo Clinic AI algorithm proves effective at spotting early-stage heart disease in routine EKG data

Mayo Clinic struck two joint ventures to develop and commercialize AI diagnostic tools. The idea was to develop algorithms to support clinicians’ decisions, starting with a suite of cardiology tools. The news comes a little over a month after Mayo Clinic announced it plans to create an “AI factory” as it expands its partnership with Google.

Mayo Clinic launches two joint ventures to build, commercialize diagnostic AI tools

Mayo Clinic has developed health technology to deliver clinical decision support tools, diagnostic insights and care recommendations so clinicians can make faster and more accurate diagnoses and provide continuous care to patients.

Mayo Clinic platform aids clinical decisions

An exclusive Tech Tribune Q&A with Venky Soundararajan (co-founder and CSO) of nference, which was honored in our: 2022, 2021, 2020 Best Tech Startups in Cambridge. 

Profile of a Founder: Venky Soundarajan

An artificial-intelligence algorithm developed at Mayo Clinic could identify left ventricular dysfunction—or a weak heart pump—in most patients based on Apple Watch data, researchers shared at a conference Sunday.

Mayo-developed AI detects heart condition from Apple Watch ECGs

Mayo Clinic announced a new technology platform initiative designed to deliver clinical decision support tools, diagnostic insights and care recommendations to help clinicians make faster and more accurate diagnoses and provide continuous care to patients.

Mayo Clinic Launches AI-Focused Diagnostic Platform Ventures

Mayo Clinic shared results of a study showing that an AI tool developed by the system could be used to improve diagnosis of low ejection fraction, a type of heart disease. It's part of a broader push by Mayo Clinic to commercialize AI-based diagnostic tools, starting with spinout company Anumana.

Mayo Clinic finds algorithm helped clinicians detect heart disease, as part of broader AI diagnostics push

Mayo Clinic has launched two new companies to support its new technology initiative, the Remote Diagnostics and Management Platform. The solution applies artificial intelligence to derive insights from data and uses these findings to support human decision-making within existing clinical workflows. It supports “event-driven medicine” by aiming to provide insights in the right context at the right time.

Mayo Clinic launches two new companies

An AI algorithm developed by researchers at the Mayo Clinic through its newly formed health technology company Anumana Inc., can assess for low ejection fraction through routine electrocardiograms (ECG, or also called EKG). The ECG-based AI-powered clinical decision support tool can enable diagnosis of low ejection fraction, especially in its earliest stages to facilitate more prompt diagnosis and treatment of the heart condition. In a clinical trial that evaluated the tool, the researchers found that it was able to detect an increased number of low ejection fraction cases in the earliest stages of the condition.

How a New AI Algorithm Could Help in the Early Detection of Heart Disease

One of the most consequential applications of artificial intelligence (AI) and machine learning (ML) is medicine. Though medical AI is still in its infancy, experts predict that within the next decade, AI-powered technology will enable healthcare providers to dramatically increase the speed, accuracy and quality of medical care from diagnosis to recovery. At the forefront of this endeavor is Mayo Clinic.

Inside Mayo Clinic’s AI Factory: How Mayo Clinic is looking to use AI to enhance patient care and clinical decision making

Mayo Clinic announced a new technology platform initiative to deliver the next generation of clinical decision support tools, diagnostic insights and care recommendations to help clinicians make faster and more accurate diagnoses and provide truly continuous care to patients. The Remote Diagnostics and Management Platform (RDMP) connects data with innovative new artificial intelligence (AI) algorithms and augments human decision-making within existing clinical workflows. RDMP enables "event-driven medicine," providing insights in the right context, at the right time.

Midwest providers eye new financial opportunities

One of the companies, Anumana, is seeking clearance from the Food and Drug Administration to market an artificial-intelligence tool to detect heart conditions.

Mayo Clinic launches two tech companies

Heart disease can take a number of forms, but some types of heart disease, such as asymptomatic low ejection fraction, can be hard to recognize, especially in the early stages when treatment would be most effective. The ECG AI-Guided Screening for Low Ejection Fraction, or EAGLE, trial set out to determine whether an artificial intelligence (AI) screening tool developed to detect low ejection fraction using data from an EKG could improve the diagnosis of this condition in routine practice. Study findings are published in Nature Medicine.

Trial demonstrates early AI-guided detection of heart disease in routine practice

Researchers in Future Healthcare Journal say that while there are claims from organizations that they’ve developed an AI solution that can “diagnose and treat a disease with equal or greater accuracy than human clinicians,” most of them are based on radiological image analysis. A survey of health care leaders found that while 58 percent are using AI in clinical practice, the most common applications are all related to imaging. 

Promising AI clinical use cases beyond imaging

Rochester, Minn.-based Mayo Clinic launched two new companies to support its newly developed Remote Diagnostics and Management Platform, which connects data with artificial intelligence technologies for clinical decision support.

Mayo Clinic launches 2 companies in support of new health analytics platform initiative

The Minnesota-based health care system announced the formation of Anumana Inc. to commercialize artificial intelligence-enabled algorithms and Lucem Health to curate data collected from remote monitoring devices.

Mayo Clinic Launches Two Companies To Support New Remote Monitoring Initiative

Mayo Clinic launches new technology platform ventures to revolutionize diagnostic medicine

Mayo Clinic announced a new technology platform and launched two new companies April 14 that promise to improve doctors’ ability to spot disease early by connecting data from remote medical devices with AI-enabled algorithms. The first target is the heart.

New Ventures To Use AI To Target Heart Disease

Mayo Clinic is launching two new companies as part of its bid to harness patient data and use it to deliver AI-guided care.

Mayo Clinic launches two companies to tap patient data for AI tools

Heart disease can take a number of forms, but some types of heart disease, such as asymptomatic low ejection fraction, can be hard to recognize, especially in the early stages when treatment would be most effective. The ECG AI-Guided Screening for Low Ejection Fraction, or EAGLE, trial set out to determine whether an artificial intelligence (AI) screening tool developed to detect low ejection fraction using data from an EKG could improve the diagnosis of this condition in routine practice. Study findings are published in Nature Medicine.

For years, data analytics in healthcare has been a frequent buzzword among industry leaders. The ability to leverage AI, machine learning, and other technologies to gain actionable insights from massive amounts of data is an exciting prospect, but one that has been notoriously difficult to realize. With the onset of the pandemic, healthcare was forced to come face-to-face with its many data challenges, from collection to accuracy and analysis. In response, the industry has ramped up its efforts to improve data analytics capabilities – with tech companies playing a major role. 

Tech Companies Aim to Expand Use of Data Analytics in Healthcare

Mayo Clinic has launched a new initiative to collect and analyze patient data from remote monitoring devices and diagnostic tools and to use artificial intelligence to accelerate diagnoses and disease prediction. To support this effort, the hospital is launching two new companies, Anumana and Lucem Health, which are working with AI and medical algorithms that tap into the hospital's patient data.

Mayo Clinic launches 2 new companies to use patient data and AI to advance early disease detection

Mayo Clinic has announced a new technology platform initiative to new clinical decision support tools, diagnostic insights, and care recommendations to help clinicians make faster and more accurate diagnoses and provide continuous care to patients.

Mayo Clinic launches two new tech companies

Artificial Intelligence (AI) continues to improve the healthcare industry. Capitalizing on AI’s many applications, Mayo Clinic is currently launching two new ventures, Anumana and Lucem Health, in order to utilize AI capabilities for preventative and diagnostic care. 

Mayo Clinic Launches Two Companies To Improve AI Diagnostic And Preventative Care

If 2020 was a strange year for Boston's startups, companies and nonprofits, 2021 was its equally weird sequel. But the continuing pandemic, global supply-chain shortages, economic turmoil and a remote work revolution haven't stopped them from innovating.

BOSTINNO'S 2021 INNO ON FIRE: Meet the 50 startups and individuals setting Boston's innovation ecosystem ablaze.

The EAGLE—short for ECG AI-Guided Screening for Low Ejection Fraction—trial attempted to establish whether an artificial intelligence (AI) screening tool designed to spot low ejection fraction through EKG data could enhance the diagnosis of this medical disorder in regular practice. The results of the study have been published in the Nature Medicine journal.